A
AION Medicines develops ultra-long-acting injectable medicines designed to improve patient adherence and treatment outcomes for chronic diseases. Their approach focuses on achieving lower peak drug concentrations for better tolerability while maintaining higher trough concentrations for continuous target engagement. The company is advancing candidates like AM-710 for Type II Diabetes and Obesity, aiming for dosing intervals of three to six months or longer.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- AION Medicines develops ultra-long-acting injectable medicines designed to improve adherence and efficacy for patients managing chronic diseases. Their approach focuses on achieving lower peak concentrations for better tolerability while maintaining higher trough levels for continuous target engagement. The company is advancing candidates like AM-710 for Type II Diabetes and Obesity, aiming for dosing intervals of three to six months or longer.